Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy
Ada S Cheung, Casey de Rooy, Rudolf Hoermann, Daryl Lim Joon, Jeffrey D Zajac, Mathis Grossmann
CLINICAL ENDOCRINOLOGY | WILEY | Published : 2017
OBJECTIVE: While androgen deprivation therapy (ADT) has been associated with decreased quality of life (QoL), controlled prospective studies are lacking. We aimed to assess QoL during ADT using two validated questionnaires and determine contributing factors. DESIGN: Prospective controlled study. PATIENTS: Sixty-three men with nonmetastatic prostate cancer newly commencing ADT (n = 34) and age- and radiotherapy-matched prostate cancer controls (n = 29). MEASUREMENTS: QoL was measured by Short-Form 12 version 2 survey (SF-12) and Aging Males' Symptoms (AMS) score at 0, 6 and 12 months. Generalized linear models determined the mean adjusted difference (MAD) (95% confidence interval) between gro..View full abstract
Related Projects (3)
National Health and Medical Research Council of Australia.